( January 14, 2025, 2:33 PM EST) -- WASHINGTON, D.C. — A maker of generic drugs on Jan. 13 told the Federal Circuit U.S. Court of Appeals that it should deny Novartis Pharmaceuticals Corp.’s motion to expedite the issuance of its mandate, saying the motion comes too soon after the appeals court’s Jan. 10 finding that a district judge was right to reject arguments that a Novartis heart failure drug patent was invalid as obvious but wrong to hold that the claims were invalid for lack of written description....